Abstract |
Helicobacter bilis, an unusual cause of chronic infections in patients with X-linked agammaglobulinemia (XLA), is notoriously difficult to diagnose and eradicate. Based on the limited number of cases reported worldwide, we highlight the typical features of H. bilis infection in XLA and provide a rational and successful approach to diagnosis and treatment of this challenging infection.
|
Authors | Stuart E Turvey, Sara H Leo, Annette Boos, Gregory D Deans, Julie Prendiville, Richard I Crawford, Christof Senger, Mary Ellen Conley, Peter Tilley, Anne Junker, Loretta Janz, Robert Azana, Linda Hoang, Tracy L Morton |
Journal | Journal of clinical immunology
(J Clin Immunol)
Vol. 32
Issue 6
Pg. 1404-8
(Dec 2012)
ISSN: 1573-2592 [Electronic] Netherlands |
PMID | 22843217
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Anti-Bacterial Agents
- beta-Lactams
- Azithromycin
- Ofloxacin
- Ertapenem
|
Topics |
- Adolescent
- Adult
- Agammaglobulinemia
(complications, diagnosis, drug therapy, pathology)
- Anti-Bacterial Agents
(therapeutic use)
- Azithromycin
(therapeutic use)
- Chronic Disease
- Ertapenem
- Genetic Diseases, X-Linked
(complications, diagnosis, drug therapy, pathology)
- Helicobacter
(drug effects, genetics, pathogenicity)
- Helicobacter Infections
(complications, diagnosis, drug therapy, pathology)
- Humans
- Male
- Ofloxacin
(therapeutic use)
- Phylogeny
- Treatment Outcome
- beta-Lactams
(therapeutic use)
|